Potential prognostic and therapeutic role for angiogenesis markers in laryngeal carcinoma

Acta Oto-Laryngologica

Volumn 132, Issue 6, 2012, Pages 574-582

  Lionello, Marco ^a   Staffieri, Alberto ^a   Marioni, Gino ^a  

^a Otolaryngology Section   (Italy)

Author keywords

Biological markers; Prognosis; Targeted therapy

Indexed keywords

ANGIOGENIN; BEVACIZUMAB; CD31 ANTIGEN; CD34 ANTIBODY; CETUXIMAB; CYCLOOXYGENASE 2; DISODIUM HYDROGEN PHOSPHATE; ENDOGLIN; ENDOSTATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; GALECTIN 1; GALECTIN 3; HYPOXIA INDUCIBLE FACTOR 1; INDUCIBLE NITRIC OXIDE SYNTHASE; NAVELBINE; SORAFENIB; SUNITINIB; TUMOR MARKER; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER PROGNOSIS; DISEASE MARKER; HUMAN; IN VIVO STUDY; LARYNGEAL SQUAMOUS CELL CARCINOMA; LARYNX CARCINOMA; MEDLINE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SQUAMOUS CELL CARCINOMA; UPREGULATION;

CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; HUMANS; LARYNGEAL NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84861081306     PISSN: 00016489     EISSN: 16512553     Source Type: Journal    
DOI: 10.3109/00016489.2011.652308     Document Type: Review

References (80)

1. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000;407:249-57.
2. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70. (Pubitemid 30046295)
3. Marasà L, Tomasino RM. Cutaneous melanoma. II. Proposal of a new prognostic parameter: evaluation of neoplastic angiogenesis. Pathologica 1983;75:353-65.
4. Beatrice F, Valente G, Cammarota R, Bisciari T, Ragona R, Giusti U, et al. Laryngeal cancer and angiogenesis. Acta Otorhinolaryngol Ital 1996;16:355-62.
5. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of eighteen major cancers in 1985. Int J Cancer 1993;54:594-606.
6. Cooper JS, Porter K, Mallin K, Hoffman HT, Weber RS, Ang KK, et al. National Cancer Database report on cancer of the head and neck: 10-year update. Head Neck 2009;31: 748-58.
7. Almadori G, Bussu F, Cadoni G, Galli J, Paludetti G, Maurizi M. Molecular markers in laryngeal squamous cell carcinoma: towards an integrated clinico biological approach. Eur J Cancer 2005;47:683-93. (Pubitemid 40342550)
8. American Cancer Society. Cancer Facts & Figures 2010. Atlanta, GA: American Cancer Society. 2010.
9. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, et al. Cancer statistics, 2006. CA Cancer J Clin 2006;56:106-30.
10. Vlachtsis K, Nikolaou A, Markou K, Fountzilas G, Daniilidis I. Clinical and molecular prognostic factors in operable laryngeal cancer. Eur Arch Otorhinolaryngol 2005;262:890-8. (Pubitemid 41779880)
11. Gisterek I, Sedlaczek P, Kornafel J, Har?oziñska-Szmyrka A, Lacko A. Serum vascular endothelial growth factor in patients with pharyngeal and laryngeal squamous cell carcinoma treated with radiotherapy. Am J Otolaryngol 2007;28: 73-7. (Pubitemid 46386312)
12. Murray JD, Carlson GW, McLaughlin K, Pennington M, Lynn M, DeRose PB, et al. Tumor angiogenesis as a prognostic factor in laryngeal cancer. Am J Surg 1997; 174:523-6. (Pubitemid 27486018)
13. Kamijo T, Yokose T, Hasebe T, Yonou H, Hayashi R, Ebihara S, et al. Image analysis of microvessel surface area predicts radiosensitivity in early-stage laryngeal carcinoma treated with radiotherapy. Clin Cancer Res 2001;7:2809-14. (Pubitemid 32911389)
14. Li J, Tang L, Ren Z, Pan Z. Distribution and prognostic significance of microvessel density in supraglottic laryngeal squamous cell carcinomas. Lin Chuang Er Bi Yan Hou Ke Za Zhi 2004;18:513-15.
15. Shigyo H, Nonaka S, Katada A, Bandoh N, Ogino T, Katayama A, et al. Inducible nitric oxide synthase expression in various laryngeal lesions in relation to carcinogenesis, angiogenesis, and patients' prognosis. Acta Otolaryngol 2007;127:970-9. (Pubitemid 47345804)
16. Zhang S, Hayashi R, Fujii M, Hasegawa Y, Yoshino K, Fukayama M, et al. Total microvessel perimeter per tumor area is a predictor of radiosensitivity in early-stage glottic carcinoma. Int J Radiat Oncol Biol Phys 2009;73:1104-9.
17. Pignataro L, Carboni N, Midolo V, Bertolini F, Buffa R, Cesana BM, et al. Clinical relevance of microvessel density in laryngeal squamous cell carcinomas. Int J Cancer 2001;92: 666-70. (Pubitemid 32385707)
18. Pietruszewska W, Kobos J, Gryczyn'ski M. Microvessel density and endothelial area in assessment of angiogenesis in patients with laryngeal cancer. Otolaryngol Pol 2003;57: 5-15.
19. Haugen H, Magnusson B, Svensson M, Mercke C. Preradiotherapy hemoglobin level but not microvessel density predicts locoregional control and survival in laryngeal cancer treated with primary radical radiotherapy. Clin Cancer Res 2004;10:7941-9. (Pubitemid 39587534)
20. Rodrigo JP, Cabanillas R, Chiara MD, García Pedrero J, Astudillo A, Suárez Nieto C.Prognostic significance of angiogenesis in surgically treated supraglottic squamous cell carcinomas of the larynx]. Acta Otorrinolaringol Esp 2009 60:272-7; in Spanish
21. Liu Y, Xue X, Wang F. The expressions of TP, MK and CD105 in laryngeal squamous cell carcinoma and their clinical significance. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2008;22:100-3.
22. Marioni G, Ottaviano G, Giacomelli L, Staffieri C, Casarotti-Todeschini S, Bonandini E, et al. CD105-assessed micro-vessel density is associated with malignancy recurrence in laryngeal squamous cell carcinoma. Eur J Surg Oncol 2006;32:1149-53. (Pubitemid 44774411)
23. Marioni G, Giacomelli L, D'Alessandro E, Staffieri C, Guzzardo V, Staffieri A, et al. Laryngeal carcinoma recurrence rate and disease-free interval are related to CD105 expression but not to vascular endothelial growth factor 2 (Flk-1/Kdr) expression. Anticancer Res 2008;28: 551-8.
24. Zvrko E, Mikic A, Vuckovic L. CD105 expression as a measure of microvessel density in supraglottic laryngeal squamous cell carcinoma. Eur Arch Otorhinolaryngol 2009;266:1971-6.
25. Marioni G, Marino F, Blandamura S, D'Alessandro E, Giacomelli L, Guzzardo V, et al. Neoangiogenesis in laryngeal carcinoma: angiogenin and CD105 expression is related to carcinoma recurrence rate and disease-free survival. Histopathology 2010;57:535-43.
26. Marioni G, Blandamura S, Loreggian L, Koussis H, Lionello M, Giacomelli L, et al. Laryngeal carcinoma prognosis after postoperative radiotherapy correlates with CD105 expression, but not with angiogenin or EGFR expression. Eur Arch Otorhinolaryngol 2011;268:1779-87.
27. Zvrko E, Mikic A, Vuckovic L. Clinicopathologic significance of CD105-assessed microvessel density in glottic laryngeal squamous cell carcinoma. Auris Nasus Larynx 2010;37: 77-83.
28. Sun D, Wang Y, Liu H, Kong W, Liu B. Prognostic value of Ki67 and VEGF in squamous cell carcinoma of larynx. Lin Chuang Er Bi Yan Hou Ke Za Zhi 2006;20:246-8.
29. Liu Y, Qiu Y, Zhang X, Tian Y, Huang D, Zhou X, et al. The expression and correlation of HMGB1 and VEGF protein in laryngeal squamous cell carcinoma. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2011;25:265-9.
30. Rueda A, Cazorla O, Pérez L, Álvarez M, Redondo M, Gallego E, et al. Vascular endothelial growth factor and vascular endothelial growth factor receptor-2 tumor expression in patients with advanced laryngeal cancer after induction chemotherapy for organ preservation. Head Neck 2011; 33:808-16.
31. Schrijvers ML, van der Laan BF, de Bock GH, Pattje WJ, Mastik MF, Menkema L, et al. Overexpression of intrinsic hypoxia markers HIF1alpha and CA-IX predict for local recurrence in stage T1-T2 glottic laryngeal carcinoma treated with radiotherapy. Int J Radiat Oncol Biol Phys 2008;72: 161-9.
32. Xu CZ, Dong P, Li XY, Zhang ZJ. Expression and clinical significance of hypoxia-inducible factor-1alpha and cyclooxygenase-2 in laryngeal squamous cell carcinoma. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2009; 44:57-62.
33. Lin P, Wang W, Cai WJ, Han CR, Sun Y, Li M, et al. Relationship between the expression of hypoxia-inducible factor-1alpha and epidermal growth factor receptor and micro vessel density and their clinical significance. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2009;44:480-5.
34. Cabanillas R, Rodrigo JP, Secades P, Astudillo A, Nieto CS, Chiara MD. The relation between hypoxia-inducible factor (HIF)-1alpha expression with p53 expression and outcome in surgically treated supraglottic laryngeal cancer. J Surg Oncol 2009;99:373-8.
35. Resnick JM, Uhlman D, Niehans GA, Gapany M, Adams G, Knapp D, et al. Cervical lymph node status and survival in laryngeal carcinoma: prognostic factors. Ann Otol Rhinol Laryngol 1995;104:685-94.
36. Wen QH, Miwa T, Yoshizaki T, Nagayama I, Furukawa M, Nishijima H. Prognostic value of EGFR and TGF-alpha in early laryngeal cancer treated with radiotherapy. Laryngoscope 1996;106:884-8. (Pubitemid 26242129)
37. Song J, Liu Q. Epidermal growth factor receptor expression in laryngeal cancer. Zhonghua Er Bi Yan Hou Ke Za Zhi 1996;31:175-7.
38. Almadori G, Cadoni G, Galli J, Ferrandina G, Scambia G, Exarchakos G, et al. Epidermal growth factor receptor expression in primary laryngeal cancer: an independent prognostic factor of neck node relapse. Int J Cancer 1999; 84:188-91. (Pubitemid 29133831)
39. Watanabe H, Suzuki T, Ito Y, Mizuta K, Sawai S, Miyata H. Prognostic significance of EGFR and p53 expression, and angiogenesis in laryngeal squamous cell carcinoma. Nihon Jibiinkoka Gakkai Kaiho 1999;102:243-53.
40. Demiral AN, Sarioglu S, Birlik B, Sen M, Kinay M. Prognostic significance of EGF receptor expression in early glottic cancer. Auris Nasus Larynx 2004;31:417-24. (Pubitemid 39575001)
41. Pivot X, MagnéN, Guardiola E, Poissonnet G, Dassonville O, Francoual M, et al. Prognostic impact of the epidermal growth factor receptor levels for patients with larynx and hypopharynx cancer. Oral Oncol 2005;41:320-7. (Pubitemid 40320461)
42. Eriksen JG, Buffa FM, Alsner J, Steiniche T, Bentzen SM, Overgaard J. Molecular profiles as predictive marker for the effect of overall treatment time of radiotherapy in supraglottic larynx squamous cell carcinomas. Radiother Oncol 2004;72: 275-82. (Pubitemid 39265380)
43. Ahmed WA, Suzuki K, Imaeda Y, Horibe Y. Ki-67, p53 and epidermal growth factor receptor expression in early glottic cancer involving the anterior commissure treated with radiotherapy. Auris Nasus Larynx 2008;35:213-19. (Pubitemid 351474584)
44. Rafferty M, Helliwell TR, Husband DJ, Fenton J, Jones TM, Jones AS. Expression of cell cycle associated proteins influences radiocurability of T2N0 squamous cell carcinoma of the larynx. Oral Oncol 2008;44:975-81.
45. Farhadieh RD, Salardini A, Rees CG, Russell PJ, Yang JL, Smee R. Protein expression of epidermal growth factor receptor in laryngeal squamous cell carcinoma index tumors correlates with diagnosis of second primary tumors of the upper aero-digestive tract. Ann Surg Oncol 2009;16:2888-94.
46. Jiang H, Yang BB. p53, epidermal growth factor receptor and proliferating cell nuclear antigen in laryngeal squamous cell carcinoma are not predictive markers for the effect of adjuvant radiotherapy. Acta Otolaryngol 2009;129:101-7.
47. Marioni G, Staffieri A, Bertolin A, Giacomelli L, D'Alessandro E, Ottaviano G, et al. Laryngeal carcinoma lymph node metastasis and disease-free survival correlate with MASPIN nuclear expression but not with EGFR expression: a series of 108 cases. Eur Arch Otorhinolaryngol 2010;267:1103-10.
48. Saussez S, Decaestecker C, Cludts S, Ernoux P, Chevalier D, Smetana K Jr, et al. Adhesion/growth-regulatory tissue lectin galectin-1 in relation to angiogenesis/lymphocyte infiltration and prognostic relevance of stromal up-regulation in laryngeal carcinomas. Anticancer Res 2009;29:59-65.
49. Piantelli M, Iacobelli S, Almadori G, Iezzi M, Tinari N, Natoli C, et al. Lack of expression of galectin-3 is associated with a poor outcome in node-negative patients with laryngeal squamous-cell carcinoma. J Clin Oncol 2002;20:3850-6.
50. Miranda FA, Hassumi MK, Guimarães MC, Simões RT, Silva TG, Lira RC, et al. Galectin-3 overexpression in invasive laryngeal carcinoma, assessed by computer-assisted analysis. J Histochem Cytochem 2009;57:665-73.
51. Des Guetz G, Uzzan B, Nicolas P, Cucherat M, Morere JF, Benamouzig R, et al. Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature. Br J Cancer 2006;94:1823-32. (Pubitemid 43882572)
52. Gasparini G, Bevilacqua P, Bonoldi E, Testolin A, Galassi A, Verderio P, et al. Predictive and prognostic markers in a series of patients with head and neck squamous cell invasive carcinoma treated with concurrent chemoradiation therapy. Clin Cancer Res 1995;11:1375-83.
53. Mosch B, Reissenweber B, Neuber C, Pietzsch J. Eph receptors and ephrin ligands: important players in angiogenesis and tumor angiogenesis. J Oncol 2010;2010:135285.
54. Tanaka F, Ishikawa S, Yanagihara K, Myahara R, Kawano Y, Li M, et al. Expression of angiopoietins and its clinical significance in non-small cell lung cancer. Cancer Res 2002;62:7124-9. (Pubitemid 35424109)
55. De Vita F, Orditura M, Lieto E, Infusino S, Morgillo F, Martinelli E, et al. Elevated perioperative serum vascular endothelial growth factor levels in patients with colon carcinoma. Cancer 2004;100:270-8. (Pubitemid 38063634)
56. Lee SJ, Kim JG, Sohn SK, Chae YS, Moon JH, Kim SN, et al. No association of vascular endothelial growth factor-A (VEGF-A) and VEGF-C expression with survival in patients with gastric cancer. Cancer Res Treat 2009;41: 218-23.
57. Lim SC. Expression of c-erbB receptors, MMPs and VEGF in head and neck squamous cell carcinoma. Biomed Pharmacother 2005;59:366-9.
58. Yaylaci A, Cakir S, Günes P, Akkaynak AC, Naiboǧlu B, Gökçeer T. The correlation of vascular endothelial growth factor with angiogenesis and p53 gene in laryngeal squamous cell carcinoma. Kulak Burun Bogaz Ihtis Derg 2006;16:105-11.
59. Scaltriti M, Baselga J. The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res 2006;12:5268-72. (Pubitemid 44497237)
60. Katona TM, Neubauer BL, Iversen PW, Zhang S, Baldridge LA, Cheng L. Elevated expression of angiogenin in prostate cancer and its precursors. Clin Cancer Res 2005; 11:8358-63. (Pubitemid 41746948)
61. Tello-Montoliu A, Patel JV, Lip GYH. Angiogenin: a review of the pathophysiology and potential clinical applications. J Thromb Haemost 2006;4:1864-74. (Pubitemid 44226759)
62. Yoshioka N, Wang L, Kishimoto K, Tsuji T, Hu GF. A therapeutic target for prostate cancer based on angiogeninstimulated angiogenesis and cancer cell proliferation. Proc Natl Acad Sci USA 2006;103:14519-24. (Pubitemid 44484782)
63. Gougos A, Letarte M. Biochemical characterization of the 44G4 antigen from the HOON pre-B leukemic cell line. J Immunol 1988;141:1934-40.
64. Schimming R, Reusch P, Kuschnierz J, Schmelzeisen R. Angiogenic factors in squamous cell carcinoma of the oral cavity: do they have prognostic relevance? J Craniomaxillofac Surg 2004;32:176-81. (Pubitemid 38684499)
65. Gao X, Huang Y, Liu J. The expressions and correlation of AQP1 and VEGF in laryngeal squamous cell carcinoma. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2009; 23:407-10.
66. Xu G, Lou W, Sun Z, Zhang P. Expression of angiopoietin-1,2 and its relationship with angiogenesis in laryngeal squamous cell carcinoma. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2008;22:772-6.
67. Paglin S, Lee NY, Nakar C, Fitzgerald M, Plotkin J, Deuel B, et al. Rapamycin-sensitive pathway regulates mitochondrial membrane potential, autophagy, and survival in irradiated MCF-7 cells. Cancer Res 2005;65:11061-70. (Pubitemid 41713377)
68. Marioni G, Staffieri A, Giacomelli L, Lionello M, Guzzardo V, Busnardo A, et al. Mammalian target of rapamycin expression and laryngeal squamous cell carcinoma prognosis: novel preliminary evidence. Histopathology 2011;58:1148-56.
69. Prince A, Aguirre-Ghizo J, Genden E, Posner M, Sikora A. Head and neck squamous cell carcinoma: new translational therapies. Mt Sinai J Med 2010;77:684-99.
70. Olszewski E. Blood vascular system in cancer of the larynx. Arch Otolaryngol 1976;102:65-70.
71. Ferrara N. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin Oncol 2002;29:10-14.
72. Crawford Y, Ferrara N. VEGF inhibition: insights from preclinical and clinical studies. Cell Tissue Res 2009;335: 261-9.
73. Zhang W, Zhu XD, Sun HC, Xiong YQ, Zhuang PY, Xu HX, et al. Depletion of tumor-associated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and antiangiogenic effects. Clin Cancer Res 2010;16:3420-30.
74. Massa E, Dessì M, Gaspardini G, Saba F, Cherchi V, Mantovani G. Phase II study of vinorelbine/cetuximab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck progressing after at least two chemotherapy regimens. Oral Oncol 2010;46:818-21.
75. Habl G, Jensen AD, Potthoff K, Uhl M, Hof H, Hajda J, et al. Treatment of locally advanced carcinomas of head and neck with intensity-modulated radiation therapy (IMRT) in combination with cetuximab and chemotherapy: the REACH protocol. BMC Cancer 2010; 10:651.
76. Wei Q, Shui Y, Zheng S, Wester K, Nordgren H, Nygren P, et al. EGFR, HER2, and HER3 expression in laryngeal primary tumors and corresponding metastases. Ann Surg Oncol 2008;15:1193-201.
77. Masood R, Gordon EM, Whitley MD, Wu BW, Cannon P, Evans L, et al. Retroviral vectors bearing IgG-binding motifs for antibody-mediated targeting of vascular endothelial growth factor receptors. Int J Mol Med 2001;8:335-43.
78. Liu J, Sheng W, Xie Y, Shan Y, Miao J, Xiang J, et al. The in vitro and in vivo antitumor activity of adenovirus-mediated interleukin-24 expression for laryngocarcinoma. Cancer Biother Radiopharm 2010;25:29-38.
79. Thorpe PE. Vascular targeting agents as cancer therapeutics. Clin Cancer Res 2004;10:415-27. (Pubitemid 38173977)
80. Fonsatti E, Del Vecchio L, Altomonte M, Sigalotti L, Nicotra MR, Coral S, et al. Endoglin: an accessory component of the TGF-b-binding receptor-complex with diagnostic, prognostic, and bioimmunotherapeutic potential in human malignancies. J Cell Physiol 2001;188:1-7. (Pubitemid 32476491)